PAR-22-035: Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
Closed
This grant is closed. A newer notice from the same program is open now: Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional) (PAR-25-281). Status: Due dates in the notice, expires January 7, 2028. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on January 7, 2023.
From the official notice on Grants.gov, last changed January 6, 2023. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsOptional
- Funded byNIMH
- Median yearly award$813,310
- Typical project length5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under PAR-22-035 were run by National Institute of Mental Health (NIMH, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
This notice replaced RFA-MH-21-105.
Application due dates, page limits and budget limits are set in the notice. Read PAR-22-035 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-25-281 | November 22, 2024 | Due dates in the notice, expires January 7, 2028 | Open |
| PAR-23-097 | January 6, 2023 | Closed November 21, 2024 | Closed |
Key dates
| Posted | September 20, 2021 |
|---|---|
| Deadline | January 7, 2023 |
| Archived by Grants.gov | February 6, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Most of the program's money (69% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Reissue of RFA-MH-21-105 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work.
Funded under PAR-22-035 so far
NIH funded 1 project under PAR-22-035 in fiscal 2023 to 2026, at 1 institution. The median yearly award was $813,310.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| PREMAP - Predictors and Risk Evaluation for Menopause-Associated Psychosis | Yale University | 2026 | $805,076 |
Who has won Mental Health Research Grants grants before
From fiscal 2021 to 2025, Mental Health Research Grants (93.242) awarded $8.8 billion across 6,785 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 185 | $371 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 200 | $297 million |
| University of California, Los Angeles | California | 176 | $234 million |
| Icahn School of Medicine at Mount Sinai | New York | 144 | $212 million |
| The Washington University | Missouri | 149 | $211 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PAR-25-281, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-22-035 still open?
No. It closed on January 7, 2023. A newer notice is open: PAR-25-281, due dates in the notice, expires January 7, 2028.
Who can apply for Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)?
Closed January 7, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-22-035?
NIH RePORTER lists 1 project funded under PAR-22-035 in fiscal 2023 to 2026, at 1 institution.
Who has won Mental Health Research Grants grants before?
The largest recipients over five fiscal years were Yale Univ, University of Pittsburgh - of the Commonwealth System of Higher Education, University of California, Los Angeles. The program made 6,785 awards worth $8.8 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)